Analysts Conflicted on These Healthcare Names: Align Tech (ALGN), Chemed (CHE) and Icon (ICLR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Align Tech (ALGN – Research Report), Chemed (CHE – Research Report) and Icon (ICLR – Research Report).

Align Tech (ALGN)

Bank of America Securities analyst Michael Ryskin reiterated a Sell rating on Align Tech yesterday and set a price target of $270.00. The company’s shares closed last Wednesday at $339.85, close to its 52-week high of $371.99.

According to TipRanks.com, Ryskin is a 2-star analyst with an average return of 1.0% and a 46.3% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Elanco Animal Health, and Illumina.

Currently, the analyst consensus on Align Tech is a Moderate Buy with an average price target of $343.33.

See the top stocks recommended by analysts >>

Chemed (CHE)

Bank of America Securities analyst Joanna Gajuk reiterated a Buy rating on Chemed today and set a price target of $610.00. The company’s shares closed last Wednesday at $566.64, close to its 52-week high of $570.17.

According to TipRanks.com, Gajuk is a 3-star analyst with an average return of 4.9% and a 68.9% success rate. Gajuk covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, US Physical Therapy, and Option Care Health.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Chemed with a $610.00 average price target.

Icon (ICLR)

Bank of America Securities analyst Derik De Bruin maintained a Buy rating on Icon yesterday and set a price target of $270.00. The company’s shares closed last Wednesday at $253.10.

According to TipRanks.com, Bruin is a 4-star analyst with an average return of 5.1% and a 52.9% success rate. Bruin covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Charles River Labs, and Quest Diagnostics.

Currently, the analyst consensus on Icon is a Strong Buy with an average price target of $270.25, which is an 8.9% upside from current levels. In a report issued on July 11, Mizuho Securities also maintained a Buy rating on the stock with a $274.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALGN:

• ALGN Earnings this Week: How Will it Perform?
• Stifel excited longer-term for Align, says near-term checks ‘relatively modest’
• Early notable gainers among liquid option names on July 10th
• Align Technology downgraded to Mixed from Positive view at OTR Global
• Insiders Pour Millions Into These 2 Stocks, Morgan Stanley Says They Have up to 140% Upside — Here’s Why You Should Pay Attention